The prevalence, risk factors and outcomes of retinopathy of prematurity at a tertiary care centre in South Africa

Authors

DOI:

https://doi.org/10.7196/SAMJ.2025.v115i5.2936

Keywords:

prevalence, risk factors, and outcomes of retinopathy of prematurity, retinopathy of prematurity in south africa, Retinopathy of prematurity

Abstract

Background. Retinopathy of prematurity (ROP) is a significant cause of preventable blindness in premature infants. The prevalence of ROP is increasing, particularly in resource-constrained settings. Low birthweight (BW), low gestational age (GA) and other neonatal risk factors are identified as key contributors. In South Africa (SA), intravitreal bevacizumab (IVB) is commonly used for treating type 1 ROP due to its accessibility and cost-effectiveness.

Objectives. To evaluate the prevalence, risk factors and outcomes of ROP in a tertiary hospital in SA infants, with a focus on the use of IVB for type 1 ROP.

Methods. This retrospective file audit, conducted at Rob Ferreira Hospital, reviewed ROP referrals from January 2020 to December 2023. Infants were screened by a specialist ophthalmologist, and treatment with IVB was administered to those diagnosed with type 1 ROP according to the Early Treatment for Retinopathy of Prematurity study protocol. Follow-up was conducted until full vascularisation, or 60 weeks post menstrual age for the respective groups.

Results. A total of 267 infants were referred, with an ROP prevalence of 27.0%. Type 1 and type 2 ROP accounted for 31.9% and 68.1% of diagnoses, respectively. Of screened infants, 8.6% (n=23/267) required treatment with IVB, with no reported complications. Of the 72 infants diagnosed with any ROP, 40.3% did not return for follow-up until discharge was indicated.

Conclusion. This study highlights a similar ROP prevalence rate to other SA studies, but yields a markedly higher ROP treatment rate. IVB proved to be a safe and effective treatment option, with no observed complications. However, a 40.3% attrition rate underscores the need for strengthened follow-up systems and improved care pathways. Addressing follow-up challenges and exploring alternative treatment modalities, such as laser photocoagulation, may help to improve long-term outcomes for at-risk infants.

 

Author Biographies

  • D C Germishuys, Department of Ophthalmology, Rob Ferreira Hospital, Mbombela, South Africa

    Rob Ferreira Hospital, Department of Ophthalmology, Mpumalanga, Medical Officer

  • S J Biddulph, Department of Ophthalmology, Rob Ferreira Hospital, Mbombela, South Africa

    Rob Ferreira Hospital, Department of Ophthalmology, Mpumalanga, Ophthalmologist

  • B Boshoff, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

    Faculty of Medicine and Health Sciences, Stellenbosch University, Medical student

References

1. Bedrossian RH, Carmichael P, Ritter J. Retinopathy of prematurity (retrolental fibroplasia) and oxygen. Clinical study. II. Further observations on the disease. Am J Ophthalmol 1954;37(1):78-86. https://doi. org/10.1016/0002-9394(54)92034-6

2. Hellström A, Smith LE, Dammann O. Retinopathy of prematurity. Lancet 2013;382(9902):1445-1457.

https://doi.org/10.1016/s0140-6736(13)60178-6

3. Kim SJ, Port AD, Swan R. Retinopathy of prematurity: A review of risk factors and their clinical significance. Surv Ophthalmol 2018;63(5):618-637. https://doi.org/10.1016/j.survophthal.2018.04.002

4. Chiang MF, Quinn GE, Fielder AR, et al. International Classification of Retinopathy of Prematurity,

Third Edition. Ophthalmology 2021;128(10):e51-e68. https://doi.org/10.1016/j.ophtha.2021.05.031

37

5. Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med 2012;367(26):2515-2526. https://doi.org/10.1056/nejmra1208129

6. Gilbert C. Retinopathy of prematurity: A global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 2008;84(2):77-82. https://doi.org/10.1016/j. earlhumdev.2007.11.009

7. Visser L, Singh R, Young M, Lewis H, McKerrow N. Guideline for the prevention, screening and treatment of retinopathy of prematurity in South Africa. S Afr Med J 2017;107(3):215-218. https:// doi.org/10.7196/samj.6305

8. Varughese S, Gilbert C, Pieper C, Cook C. Retinopathy of prematurity in South Africa: An assessment of needs, resources and requirements for screening programmes. Br J Ophthalmol 2008;92(7):879-882. https://doi.org/10.1136/bjo.2008.137588

9. O’Sullivan J, Gilbert C, Foster A. The causes of childhood blindness in South Africa. S Afr Med J 1997;87(12):1691-1695. https://pubmed.ncbi.nlm.nih.gov/9497836/ (accessed 7 May 2025).

10. Esra N, Mayet I. The causes of visual impairment in children in a school for the blind in Johannesburg. SA Ophthalmol J 2020;15(1):26-29. https://jhbeye.com/wp-content/uploads/2020/10/Childhood- blindness-in-South-Africa.pdf (accessed 7 May 2025).

11. Onyango O, Sitati S, Amolo L, et al. Retinopathy of prematurity in Kenya: Prevalence and risk factors in a hospital with advanced neonatal care. Pan Afr Med J 2018;29:152. https://doi.org/10.11604/ pamj.2018.29.152.14046

12. Fajolu IB, Rotimi-Samuel A, Aribaba OT, et al. Retinopathy of prematurity and associated factors in Lagos, Nigeria. Paediatr Int Child Health 2015;35(4):324-328. https://doi.org/10.1080/20469047.201 5.1109277

13. Visser Kift E, Freeman N, Cook C, et al. Retinopathy of prematurity screening criteria and workload implications at Tygerberg Children’s Hospital, South Africa: A cross-sectional study. S Afr Med J 2016;106(6):602-606. https://doi.org/10.7196/SAMJ.2016.v106i6.10358

14. Keraan Q, Tinley C, Horn A, Pollock T, Steffen J, Joolay Y. Retinopathy of prematurity in a cohort of neonates at Groote Schuur Hospital, Cape Town, South Africa. S Afr Med J 2017;107(1):64-69. https:// doi.org/10.7196/samj.2016.v107.i1.11226

15. Delport SD, Swanepoel JC, Odendaal PJ, et al. Incidence of retinopathy of prematurity in very-low- birth-weight infants born at Kalafong Hospital, Pretoria. S Afr Med J 2002;92(12):986-990. https:// pubmed.ncbi.nlm.nih.gov/12561416/ (accessed 7 May 2025).

16. Kana H, Mayet I, Soma D, Dawood Alli H, Biddulph S. The efficacy of intravitreal antivascular endothelial growth factor as primary treatment of retinopathy of prematurity: Experience from a tertiary hospital. S Afr Med J 2017;107(3):215-218. https://doi.org/10.7196/SAMJ.2017.v107i3.11080

17. Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364(7):603-615. https://doi. org/10.1056/NEJMoa1007374

18. Hapsari D, Sitorus RS. Intravitreal bevacizumab in retinopathy of prematurity. Asia Pac J Ophthalmol 2014;3(6):368-378. https://doi.org/10.1097/APO.0000000000000039

19. Parliamentary Monitoring Group. STC160303: Report of the Portfolio Committee on Health on Oversight visit to Mpumalanga province from 22 to 23 September 2014, dated 24 February 2016. Parliamentary Monitoring Group, 2016. https://pmg.org.za/tabled-committee- report/2660/#:~:text=The%20hospital%20has%20a%20total,of%20stay%20of%207.3%20days (accessed 22 October 2024).

20. Good WV, Hardy RJ, Dobson V, et al. Revised indications for the treatment of retinopathy of prematurity: Results of the early treatment for retinopathy of prematurity randomised trial. Arch Ophthalmol 2003;121(12):1684-1694. https://doi.org/10.1001/archopht.121.12.1684

21. Fierson WM. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2018;142(6):e20183061. https://doi.org/10.1542/peds.2018-3061

22. Van der Merwe SK, Freeman N, Bekker A, Harvey J, Smith J. Prevalence of and risk factors for retinopathy of prematurity in a cohort of preterm infants treated exclusively with non-invasive ventilation in the first week after birth. S Afr Med J 2013;103(2):96. https://doi.org/10.7196/samj.6131

Downloads

Published

2025-06-03

Issue

Vol. 115 No. 5 (2025)

Section

Research

License

Copyright (c) 2025 D C Germishuys, S J Biddulph, B Boshoff

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Licensing Information

The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited. 

Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository. 

Publishing Rights

Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.

 

How to Cite

1.
Germishuys DC, Biddulph SJ, Boshoff B. The prevalence, risk factors and outcomes of retinopathy of prematurity at a tertiary care centre in South Africa. S Afr Med J [Internet]. 2025 Jun. 3 [cited 2025 Sep. 25];115(5). Available from: https://samajournals.co.za/index.php/samj/article/view/2936